Immunological and clinical features of psoriasis in HIV-infected patients


DOI: https://dx.doi.org/10.18565/epidem.2018.4.82-91

Evdokimov E.Yu., Sundukov A.V., Gorelova E.A.

1 Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; 2 A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
Psoriasis is a systemic chronic, immunologically mediated, genetically determined disease that depends on environmental factors. It is detected in 2-3% of the world’s population. The review presents a current view on the etiology, pathogenesis, and clinical features of psoriasis in HIV-infected patients, on treatments and the possibility of their use in this category of patients. HIV infection is noted to affect the key components of the pathogenesis of psoriatic disease. Methods of psoriasis therapy and an approach to choosing its options are displayed. The authors’ personal archive photos of HIV-infected people suffering from psoriasis vulgaris have been used. In addition to HIV infection, these patients often have comorbidities that affect the course of psoriasis. The review has been carried out using the sources available in the search systems PubMed Services, Clinical Queries, and MEDLINEPlus. Unfortunately, the currently studied etiological and pathogenetic causes of the disease are not conclusively established. In this connection, the methods of psoriasis therapy will be further changed and improved, which indicates the importance of continuing investigations of this pathology in patients with HIV infection and the development of new treatments.
Keywords: psoriasis, HIV infection
Read entire article

Literature

  1. Parisi R., Symmons D.P., Griffiths C.E., Ashcroft D.M. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 2013; 133(2): 377–85.
  2. Alexis A.F., Blackcloud P. Psoriasis in Skin of Color: Epidemiology, Genetics, Clinical Presentation and Treatment Nuances. J. Clin. Aesthet. Dermatol. 2014; 7(11): 16–24.
  3. Gelfand J.M., Weinstein R., Porter S.B., Neimann A.L., Berlin J.A., Margolis D.J. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch. Dermatol. 2005; 141(12): 1537–41.
  4. Tollefson M.M., Crowson C.S., McEvoy M.T, Kremers M.H. Incidence of psoriasis inchildren: a population-based study. J. Am. Acad. Dermatol. 2010; 62(6): 979–87. DOI:10.1016/j.jaad.2009.07.029
  5. Yeung H., Wan J., Van Voorhees A.S., Callis Duffin K., Krueger G.G., Kalb R.E. et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate-to-severe psoriasis. J. Am. Acad. Dermatol. 2013; 68(1): 64–72. DOI: 10.1016/j.jaad.2012.06.035
  6. Galezowski A., Maccari F., Hadj-Rabia S., Sigal M.L., Phan A., Lahfa M. et al. le GEM Resopso et le Groupe de recherche de la Société française de dermatologie pédiatrique. Psoriatic arthritis in France, from infants to the elderly: Findings from two cross-sectional, multicenter studies. Ann. Dermatol. Venereol. 2017; Nov 13. pii: S0151-9638(17)30968-7. [Epub ahead of print].
  7. Egeberg A., Kristensen L.E., Thyssen J.P., Gislason G.H., Gottlieb A.B., Coates L.C. et al. Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Ann. Rheum. Dis. 2017; 76(9):1 591–7. DOI: 10.1136/annrheumdis-2016-210963
  8. Zenke Y., Ohara Y., Kobayashi D., Arai S., Kishimoto M., Okada M. et al. Nail findings in patients with psoriatic arthritis: A cross-sectional study with special reference to transverse grooves. J. Am. Acad. Dermatol. 2017; 77(5): 863–7. DOI: 10.1016/j.jaad.2017.04.001.
  9. Naldi L., Mercury S.R. Epidemiology of comorbidities in psoriasis. Dermatol. Ther. 2010; 23: 114–8. DOI:10.1111/j.1529-8019.2010.01304
  10. Goulding J.M., Price C.L., Defty C.L., Hulangamuwa C.S., Bader E., Ahmed I. Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. Br. J. Dermatol. 2011; 164: 103–9.
  11. Leal L., Ribera M., Daudén E. Psoriasis and HIV infection. Actas Dermo-Sifiliográficas 2008; 99(10): 753–63.
  12. Morar N., Willis-Owen S.A., Maurer T., Bunker C.B. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect. Dis. 2010; 10(7): 470–8.
  13. Bakulev A.L.. Znamenskaya L.F.. Khobeysh M.M.. Olisova O.Yu. Bakulev A.L.. Znamenskaya L.F.. Khobeysh M.M.. Olisova O.Yu. [Federal clinical guidelines for the management of psoriasis patients]. Мoscow, 2013. URL: http://rykovodstvo.ru/exspl/48501/index.html
  14. Capon F. The Genetic Basis of Psoriasis. International Journal of Molecular Sciences 2017; 18(12): 2526. DOI: 10.3390/ijms18122526.
  15. Gervin K., Vigeland M.D., Mattingsdal M., Hammerø M., Nygаrd H., Olsen A.O. et al. DNA methylation and gene expression changes in monozygotic twins discordant for psoriasis: identification of epigenetically dysregulated genes. PLoS Genetics 2012; 8(1): e1002454. http://dx.doi.org/10.1371/journal.pgen.1002454
  16. Chen H., Hayashi G., Lai O.Y., Dilthey A., Kuebler P.J., Wong T.V. et al. Psoriasis Patients Are Enriched for Genetic Variants That Protect against HIV-1 Disease. PLoS Genet. 2012; 8(2): e1002514. https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3343879/
  17. Chandra A., Lahiri A., Senapati S., Basu B., Ghosh S., Mukhopadhyay I. et al. Increased Risk of Psoriasis due to combined effect of HLA-Cw6 and LCE3 risk alleles in Indian population. Int. J. Sci. Reports. Published online 2016 Apr 6. DOI: 10.1038/srep24059.
  18. Ogdie A., Gelfand J.M. Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: A review of available evidence. Curr. Rheumatol Rep. 2015; 17(10): 64. DOI: 10.1007/s11926-015-0540-1
  19. Liang Y., Sarkar M.K., Tsoi L.C., Gudjonsson J.E. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr. Opin. Immunol. 2017; 49: 1–8. DOI: 10.1016/j.coi.2017.07.007
  20. Tokura Y., Mori T., Hino R. Psoriasis and other Th17-mediated skin diseases. J. UOEH. 2010; 32(4): 317–28.
  21. Johnston A., Xing X., Wolterink L., Barnes D.H., Yin Z., Reingold L. et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J. Allergy Clin. Immunol. 2017; 140(1): 109–20.
  22. Hawkes J.E., Nguyen G.H., Fujita M., Florell S.R., Callis D.K., Krueger G.G., O’Connell R.M. microRNAs in Psoriasis. J. Invest. Dermatol. 2016; 136(2): 365–71. https://www.ncbi.nlm.nih.gov/pubmed/26802234.
  23. Jaehwan Kim, Pranay Nadella, Dong Joo Kim, Carrie Brodmerkel, Joel Correa da Rosa, James G. Krueger. Histological Stratification of Thick and Thin Plaque Psoriasis Explores Molecular Phenotypes with Clinical Implications. PLoS One 2015; 10(7): e0132454. DOI: 10.1371/journal.pone.0132454.
  24. Seneschal J., Clark R.A., Gehad A., Baecher-Allan C.M., Kupper T.S. Human Epidermal Langerhans Cells Maintain Immune Homeostasis in Skin by Activating Skin Resident Regulatory T Cells. Immunity 2012; 36(5): 873–84.
  25. Lowes M.A., Suárez-Fariñas M., Krueger J.G. Immunology of Psoriasis. Ann. Rev. Immunol. 2014; 32: 227–55. DOI: 10.1146/annurev-immunol-032713-120225.
  26. Klatt N.R., Funderburg N.T., Brenchley J.M. Microbial translocation, immune activation, and HIV disease. Trends in Microbiology 2013; 21: 6–13.
  27. Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009; 139: 485–98.
  28. Ortega C., Fernandez A.S., Carrillo J.M., Romero P., Molina I.J..et al. IL-17-producing CD8+ T- lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J. Leukoc. Biol. 2009; 86: 435–43.
  29. Nagendran Prabhakaran, Telanseri J. Jaisankar, Abdoul Hamide, Munisamy Malathi, Rashmi Kumari, Devinder Mohan Thappa. Effect of antiretroviral therapy on mucocutaneous manifestations among Human Immunodeficiency Virus-infected patients in a tertiary care centre in South India. Indian Journal of Sexually Transmitted Diseases and AIDS 2015; 36(2): 166–73.
  30. Aditi Chandra, Swapan Senapati, Sudipta Roy, Gobinda Chatterjee, Raghunath Chatterjee. Epigenome-wide DNA methylation regulates cardinal pathological features of psoriasis. Clin. Epigenetics 2018; 10: 108. https://doi.org/10.1186/s13148-018-0541-9
  31. Sonkoly E., Wei T., Janson P.C., Saaf A., Lundeberg L., Tengvall-Linder M., Norstedt G., Alenius H., Homey B., Scheynius A., Stahle M., Pivarcsi A. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One 2007; (2): e610.
  32. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., Robb L., Greenhalgh C.J., Forster I., Clausen B.E., Nicola N.A., Metcalf D., Hilton D.J., Roberts A.W., Alexander W.S. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 2003; (4): 540–5.
  33. Baliwag J., Barnes D.H., Johnston A. Cytokines in psoriasis. Cytokine 2015; 73(2): 342–50. DOI: 10.1016/j.cyto.2014.12.014
  34. Nograles K.E., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suarez-Farinas M., Cardinale I. et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Brit. J. Dermatol. 2008; 159: 1086–91.
  35. Iketleng T., Moyo В., Gaseitsiwe S., Nyombi B., Mitchell R.M., Makhema J. et al. Plasma Cytokine Levels in Chronic Asymptomatic HIV-1 Subtype C Infection as an Indicator of Disease Progression in Botswana: A Retrospective Case Control Study. AIDS Res. Hum. Retroviruses 2016; 32(4): 364–9. DOI: 10.1089/AID.2015.0163.
  36. Guo H., Gao J., Taxman D.J., Ting J.P.Y., Su L. HIV-1 Infection Induces Interleukin-1β Production via TLR8 Protein-dependent and NLRP3 Inflammasome Mechanisms in Human Monocytes. J. Biol. Chem. 2014; 289; 21716–26. DOI: 10.1074/jbc.M114.566620.
  37. Kimball A.B., Gladman D., Gelfand J.M., Gordon K., Horn E.J., Korman N.J. et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J. Am. Acad. Dermatol. 2008; 58: 1031–42.
  38. Jost M., Kari C., Rodeck U. The EGF receptor – an essential regulator of multiple epidermal functions. Eur. J. Dermatol. 2000; 10(7): 505–10.
  39. Adaskevich V.P. [Diagnostic indices in dermatology]. Мoscow: Izdatelstvo Panfilova; BINOM. Laboratoriya znaniy. 2014. 352 р. URL: http://binom-press.ru/books_1/dermat/diagn_ind_dermat_cont.pdf (In Russ.).
  40. Morar N., Dlova N. C., Mosam A., Aboobaker J. Cutaneous manifestations of HIV in Kwa-Zulu Natal, South Africa . Int. J. Dermatol. 2006; 45(8); 1006 – 7.
  41. Oleinik A.F., Fazylov V.Kh. [Causes of immunological inefficiency of antiretroviral therapy in patients with HIV infection]. Kazanskiy Meditsinskiy Zhurnal 2014; 95(4): 581–8. (In Russ.).
  42. Kurd S.K., Gelfand J.M.. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003–2004. J. Am. Acad. Dermatol. 2009; 60(2): 218–24.
  43. Katsambas F.D.. Lotti T.M [European guidelines for the treatment of dermatological diseases]. Мoscow: MEDpress-inform, 2014; 392–406 (In Russ.).
  44. Mrowietz U., Kragballe K., Reich K., Spuls P., Griffiths C.E.M., Nast A., Franke J. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch. Dermatol. Res. 2011; 303(1): 1–10.
  45. Papp K., Reich K., Leonardi C.L., Kircik L., Chimenti S., Langley R.G. et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J. Am. Acad. Dermatol. 2015; 73: 37–49.

For citations: Evdokimov E.Yu., Sundukov A.V., Gorelova E.A. Immunological and clinical features of psoriasis in HIV-infected patients. Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2018; (4):82–91 (In Russ.).


About the Autors

Evgeniy Y. Evdokimov, Cand. Med. Sci., Researcher, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; е-mail: evdokimovevg@yandex.ru; ORCID: http//orcid.org/ 0000-0003-2694-8900
Aleksandr V. Sundukov, MD, Professor, Department of Infectious Diseases and Epidemiology, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia; e-mail: sunducov1961@mail.ru; ORCID: http//orcid.org/0000-0002-3798-7780
Elena A. Gorelova, Cand. Med. Sci., Researcher, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; е-mail: doctorgorelovaea@yandex.ru; ORCID: http//orcid.org/ 0000-0002-3861-6375


Similar Articles

Back to Content

Бионика Медиа